New agreement replaces Risperdal co-promotion
Arnhem, the Netherlands, March 31, 2005 – Akzo Nobel’s human healthcare business, Organon, and Johnson & Johnson’s Janssen-Cilag* have mutually agreed to end their co-promotion with regard to the antipsychotic drug Risperdal®. The two companies – who have collaborated on the product since 1993 – have terminated their current arrangement in Europe, Argentina and Brazil and replaced it with a financial agreement.The need for this new agreement has arisen as a result of Organon’s development of its own antipsychotic products, notably asenapine through an alliance with Pfizer. Asenapine is